Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Regeneron develops new medicines and it rang up $3.7 billion in sales for its anti-inflammatory drug Dupixent as a treatment for eczema, asthma and chronic obstructive pulmonary disease, in its latest ...

Bayer A.G.'s stock is undervalued but faces risks with declining profits & regulatory pressures. Click for my updated look at ...

US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Detailed price information for Atlas Energy Solutions Inc Cl A (AESI-N) from The Globe and Mail including charting and trades ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.